SCHEMBL29387473

SCHEMBL29387473

CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ITGB3 P05106 1/20 0.59
▸ ITGB1 P05556 1/20 0.59
▸ ITGAV P06756 1/20 0.59
▸ ITGA5 P08648 1/20 0.59
▸ ITGB5 P18084 1/20 0.59
▸ ELANE P08246 4/20 0.56
▸ PLAU P00749 1/20 0.55
▸ CACNA1B Q00975 1/20 0.54
▸ CTSG P08311 2/20 0.52
▸ KDM4A O75164 1/20 0.51
▸ NNMT P40261 1/20 0.51
▸ KLKB1 P03952 1/20 0.48
▸ ST14 Q9Y5Y6 1/20 0.48
▸ MC4R P32245 3/20 0.46
▸ MC5R P33032 3/20 0.46
▸ MC3R P41968 3/20 0.46
▸ MC1R Q01726 3/20 0.46
▸ TNFSF11 O14788 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29388680 0.95 PLAU (0.59) ITGB3ITGB1ITGAVITGA5ITGB5
SCHEMBL29388360 0.90 ELANE (0.53) ITGB3ITGB1ITGAVITGA5ITGB5
SCHEMBL29420577 0.85 KLKB1 (0.50) ITGB3ITGB1ITGAVITGA5ITGB5
SCHEMBL13722938 0.81 PLAU (0.50) ITGB3ITGB1ITGAVITGA5ITGB5
Kalata B8 SCHEMBL30173419 0.80 CACNA1B (0.70) ITGB3ITGB1ITGAVITGA5ITGB5
Cyclorgdfv SCHEMBL25474158 0.80 ITGB3 (0.58) ITGB3ITGB1ITGAVITGA5ITGB5
Cyclorgdfv SCHEMBL29973120 0.80 ITGB3 (0.58) ITGB3ITGB1ITGAVITGA5ITGB5
Cyclorgdfv SCHEMBL19605549 0.80 ITGB3 (0.58) ITGB3ITGB1ITGAVITGA5ITGB5
Cyclorgdfv SCHEMBL19605449 0.80 ITGB3 (0.58) ITGB3ITGB1ITGAVITGA5ITGB5
SCHEMBL25473422 0.79 KDM4A (0.55) ITGB3ITGB1ITGAVITGA5ITGB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12569535-B2 Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2026-03-10 — — US claimed
CN-119614610-A Method for preventing and controlling citrus canker by using antibacterial peptide 浙江农林大学 2025-03-14 — — CN claimed
US-20250041381-A1 Prophylactic Uses of Theta Defensins UNIVERSITY OF SOUTHERN CALIFORNIA 2025-02-06 — — US claimed
EP-4426330-A1 PROPHYLACTIC USES OF THETA DEFENSINS THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2024-09-11 — — EP claimed
US-20240042024-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF IMMUNE-MEDIATED DISEASES GENERAL NANOTHERAPEUTICS LLC 2024-02-08 — — US claimed
CN-117377456-A Method for enhancing natural defenses of the oral cavity 高露洁-棕榄公司 2024-01-09 — — CN claimed
US-20230270828-A1 COMPOSITION FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BICT S.R.L. (IT) 2023-08-31 — — US claimed
WO-2023081149-A1 PROPHYLACTIC USES OF THETA DEFENSINS THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2023-05-11 — — WO claimed
CN-109248310-B Blockade of inflammatory proteases using theta-defensins 加利福尼亚大学董事会 2022-07-01 — — CN claimed
US-12569535-B2 Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2026-03-10 — — US disclosed
US-20260055151-A1 ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE LUNDQUIST INST FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL CENTER (US) 2026-02-26 — — US disclosed
US-20250295587-A1 COMPLEX LIPID NANOPARTICLES ENCAPSULATING POLYPEPTIDES AND USES THEREOF SAIL BIOMEDICINES, INC. 2025-09-25 — — US disclosed
US-12405133-B2 Magnetic indoor positioning with magnetometer calibration errors equalization ORIIENT NEW MEDIA LTD (IL) 2025-09-02 — — US disclosed
CN-120051577-A Biomarkers for predicting atopic dermatitis that promote the prevention and/or treatment of the onset of atopic dermatitis 科赴品牌有限责任公司 2025-05-27 — — CN disclosed
WO-2022104073-A1 DEFENSINS AS INHIBITORS OF SARS-COV-2 INFECTION AND USES THEREOF UNIVERSITY OF MARYLAND, BALTIMORE (US) 2022-05-19 — — WO disclosed
US-20220143052-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2022-05-12 — — US disclosed
WO-2022081973-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2022-04-21 — — WO disclosed
CN-114080394-A Novel theta-defensin analogs 迈克尔·E·塞尔斯特德 2022-02-22 — — CN disclosed
CN-114072415-A Compositions and methods for treating fungal infections 迈克尔·E·塞尔斯特德 2022-02-18 — — CN disclosed
WO-2022029577-A1 COMPOSITION FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BICT S.R.L. (IT) 2022-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143052-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF PHOSPHO1, SGMS2, SGMS1 ITGB3 2466/4885ITGB1 2941/4885ITGAV 1709/4885
US-20260055151-A1 ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE CCL5, PRKCZ, VIP ITGB3 221/4885ITGB1 615/4885ITGAV 208/4885
US-12569535-B2 Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides CFD, ARG1, IL1A ITGB3 1135/4885ITGB1 748/4885ITGAV 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback